Medical Economics January 5, 2024
New study finds prices of targeted drugs are three times higher in U.S. than elsewhere
In February 2024 the Centers for Medicare and Medicaid Services (CMS) will begin price negotiations for the first 10 drugs selected under the 2022 Inflation Reduction Act (IRA). A new study finds that the list prices for the 10 selected drugs are about three times higher in the U.S. than in other countries.
Even after rebates and discounts, prices are higher than other countries, except for Janssen’s Xarelto (rivaroxaban), according to recently released study from the Commonwealth Fund. The study found that Switzerland has the second-highest prices for most of the 10 drugs.
Researchers conducted the study using data from the consulting and biopharmaceutical company...
Today's Sponsors
Today's Sponsor